Oxford vaccine trials cleared to resume after safety alert
It has been reported that a UK participant experienced symptoms consistent with transverse myelitis
Global clinical trials for the Oxford COVID-19 vaccine have restarted after they were halted last week when a participant experienced an adverse event.
The manufacturer of the vaccine, AstraZeneca, said a woman in the UK had developed severe neurological symptoms after being administered the vaccine as part of the phase 3 trials.
No further details were provided but reports in the New York Times said